Mersana Therapeutics (MRSN) Misses Q3 EPS by 18c

Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($0.35), $0.18 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.69 million versus the consensus estimate of $7.53 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Circle board member resigns after nearly 13 years of service
• Nutrien warns shareholders about below-market mini-tender offer